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Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours to imatinib. Here, we report a case of
metastatic gastrointestinal stromal tumour that relapsed during imatinib therapy. Mutation analysis showed that the imatinib-resistant
liver tumour contained two c-kit mutations.
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Gastrointestinal stromal tumours (GISTs) are the most common
mesenchymal tumours of the human gastrointestinal tract. The
GISTs are often characterized by expression levels of KIT, a
tyrosine kinase, and many tumours contain mutations of the KIT-
encoding gene, c-kit (Hirota et al, 1998). Imatinib is a selective
tyrosine kinase inhibitor for BCR-ABL, platelet-derived growth
factor receptors, and KIT, and has a dramatic antitumour effect on
metastatic GISTs (Demetri et al, 2002). Heinrich et al (2003)
recently found a strong association between clinical response to
imatinib and tumour genotype, which has clarified our under-
standing of the molecular mechanisms underpinning primary
resistance to imatinib in GISTs. Resistance to imatinib treatment
for GISTs can also occur after the initial clinical response.
However, the mechanism for this secondary resistance to imatinib
in GISTs remains unknown.
Here, we report a case of resistance to imatinib in a patient with
metastatic GIST of gastric origin. The tumour relapsed during
imatinib treatment after showing a very good clinical response. We
also present a c-kit mutation analysis of the primary and
metastatic tumours of the patient.
CASE REPORT
A 64-year-old Japanese man underwent a proximal gastrectomy for
a KIT-positive gastric GIST. At 8 months after the gastric resection,
the patient underwent a palliative resection for peritoneal
metastases (more than 10foci with the largest being 6.5cm in
diameter). At 11 months after initial resection, computed
tomography (CT) revealed a solitary liver metastasis measuring
3.1cm in diameter and multiple peritoneal metastases, of which
the largest was 5.5cm in diameter (Figure 1A). The patient was
referred to Niigata University Medical and Dental Hospital for
imatinib treatment of the recurrent GISTs.
Imatinib treatment with four capsules of 100mg imatinib
mesylate (Glivec
s, Novartis Pharma, Basel, Switzerland) once daily
was started. After 3 months of imatinib treatment, abdominal CT
scans showed that the liver and peritoneal metastatic tumours had
reduced in size to 2.5 and 3.4cm in diameter, respectively.
Computed tomography scans conducted a further 3 months later
showed that the antitumour effect of imatinib had continued,
confirming a partial response (PR) (Figure 1B). However, 9 months
after imatinib treatment was initiated, CT and magnetic resonance
imaging (MRI) revealed disease progression at the metastatic site in
the liver (Figure 1C). The peritoneal metastases had reduced to
smaller lesions with an irregular shape and the intensity of soft
tissue. Positron-emission tomography (PET) with [
18F] fluorodeox-
yglucose ([
18F]FDG) as a tracer revealed increased uptake only in
the liver metastasis (Figure 1D), suggesting that the liver tumour
was active and insensitive to imatinib. At 12 months after the start
of imatinib treatment, the relapsing tumour in the liver was excised
with extended left hepatectomy. The patient is alive with no
evidence of disease relapse 2 months after the liver resection.
PATHOLOGICAL EXAMINATION
The resected liver specimen contained a metastatic GIST measur-
ing 5.03.2cm. The peripheral tumour showed a solid margin and
there was central necrosis with cystic change. Viable spindle-
shaped tumour cells were observed in the solid part by histology,
and immunohistochemistry revealed that the tumour cells were
KIT-positive. The proliferative activity of the tumour cells was
approximately 80% in the regrowing focus, as evaluated by the Ki-
67 labelling index (MIB1; Immunotech, Marseille, France).
MUTATION ANALYSIS OF THE c-kit GENE
RNA was isolated from fresh surgical specimens of liver metastatic
tumours and cDNA synthesis was performed. The complete coding
region of c-kit cDNA was directly sequenced using an ABI Prism
3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
The metastatic liver tumour had an in-frame mutation with a
deletion of eight amino-acid residues corresponding to codons
552–559, and a substitutive isoleucine insertion in exon 11. An
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lamino-acid substitution of codon 823-tyrosine (TAT) to aspartate
(GAT) in exon 17 was also detected in the liver tumour. Mutation
analysis of the c-kit sequence from the primary gastric GIST was
then performed. Exons 11 and 17 of the c-kit gene were amplified
by PCR using genomic DNA extracted from formalin-fixed,
paraffin-embedded tissues as previously described (Taniguchi
et al, 1999). Sequencing of the exon 11 and 17 c-kit PCR products
revealed an in-frame deletion identical to that found in the
metastatic liver tumour but no exon 17 mutation was found.
DISCUSSION
Treatment failure with imatinib is a critical problem in patients
with advanced chronic myeloid leukemia (CML) or metastatic
GIST. Here, we present a case of metastatic GISTs showing late
resistance to imatinib. DNA analysis revealed two gain-of-function
mutations of the c-kit gene in the relapsing tumours: an in-frame
mutation in exon 11, which encodes a region in the juxtamem-
brane domain; and a missense point mutation in exon 17, which
encodes the tyrosine kinase (TK2) domain. A recent analysis of 112
metastatic GISTs by Heinrich et al (2003) revealed that c-kit
mutations in exon 11 are the most common mutations found, with
an incidence of 66.9%. In contrast, mutations in exon 17 were
found in only two tumours (1.6%). In addition, this large-scale
genetic study found no GIST with an activating mutation in more
than one exon of the c-kit gene. Thus, our finding is significant in
identifying two types of gain-of-function mutations simultaneously
in one relapsing tumour focus. Moreover, the missense mutation
in exon 17 was not found in the primary GIST of the stomach. This
led us to conclude that the second mutation generated in the TK2
domain (Y823D) was responsible for the loss of sensitivity to
imatinib in the metastatic tumours.
It is known that the mutational status of c-kit affects clinical
response to imatinib in patients with metastatic GISTs (Heinrich
et al, 2003). In patients with GISTs harboring exon 11 c-kit
mutations, the PR rate was 83.5%, whereas patients with tumours
containing an exon 9 mutation or no detectable mutation had PR
rates of 47.8 and 0.0%, respectively. Exon 17 in the c-kit gene
encodes the tyrosine kinase domain of KIT kinase, which suggests
that substitution of an amino-acid residue in TK2 causes a critical
conformational change that interferes with the effectiveness of
imatinib. In CML, resistance to imatinib is conferred by a similar
mechanism involving ABL kinase; this was shown clinically and in
vitro (Gorre et al, 2001). However, data on the correlation between
mutations in exon 17 and the patient’s clinical response to
treatment have been obtained from only two patients so far: one
patient showed a partial response, while the other had a
progressive disease. More data are needed to evaluate the clinical
association of mutations in exon 17 of c-kit and sensitivity to
imatinib, particularly in metastatic foci.
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